JointMedica
UK medical device manufacturer specializing in hip arthroplasty and hip resurfacing implants.
Website: https://www.jointmedica.com
Cover Block
PUBLIC
| Name | JointMedica |
| Tagline | UK medical device manufacturer specializing in hip arthroplasty and hip resurfacing implants. |
| Headquarters | Worcester, UK |
| Founded | 2000 [Companies House] |
| Stage | Other |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Hardware |
| Geography | Western Europe |
| Growth Profile | SMB / Main Street |
| Founding Team | Other |
| Funding Label | Undisclosed |
Note: Total disclosed funding is not publicly available. The company's capitalization is private.
Links
PUBLIC The following are the primary public-facing links for JointMedica, as confirmed by the company's own materials and public registries.
- Website: https://www.jointmedica.com
- LinkedIn: https://uk.linkedin.com/company/jointmedicaltd
Executive Summary
PUBLIC
JointMedica is a UK-based medical device manufacturer whose attempt to modernize hip resurfacing for younger patients has drawn a strategic partnership and minority investment from a major US orthopaedic player, making its ongoing clinical study the critical near-term catalyst for investors. The company, incorporated in 2000, has built its business around the Polymotion® Hip Resurfacing System, a bone-preserving implant designed as an alternative to total hip replacement for active individuals [JointMedica]. Its leadership, including CEO Dr. Sharat Kusuma, brings direct industry experience from Zimmer Biomet and Exactech, providing a credible operational foundation in a sector where clinical and commercial relationships are paramount [The Silicon Review]. The company appears to be privately financed, with a single disclosed corporate round in 2022 involving Exactech, which now holds a minority stake and serves as a commercial partner for the Polymotion system [Crunchbase, Jan 2022], [BusinessWire, Jan 2023]. Over the next 12 to 18 months, the primary focus will be the progression of its US Investigational Device Exemption study, which began enrollment in early 2025 and represents the essential regulatory pathway to a potentially lucrative American market [JointMedica, 2025], [NYU Langone Health, 2026].
Data Accuracy: YELLOW -- Core business description and partnership are well-sourced; financial metrics are modeled estimates from a single provider.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Other |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Hardware |
| Geography | Western Europe |
| Growth Profile | SMB / Main Street |
| Founding Team | Other |
| Funding | Undisclosed |
Company Overview
PUBLIC
JointMedica Limited is a UK-based medical device manufacturer incorporated on 28 February 2000, operating under the SIC code for the manufacture of medical and dental instruments and supplies [Companies House]. The company, headquartered in Worcester, UK, has maintained a consistent focus on orthopaedic implants for over two decades, positioning itself as a specialist in hip arthroplasty and resurfacing technology [JointMedica].
Its operational history is marked by a significant partnership and investment event in early 2022, when US orthopaedic company Exactech participated in an undisclosed corporate funding round [Crunchbase, Jan 2022]. This transaction formalized a strategic relationship, with Exactech acquiring a minority interest in JointMedica and establishing a co-development and distribution agreement for the company's flagship Polymotion Hip Resurfacing System [Businesswire, Jan 2023]. The partnership has been central to advancing the product's clinical pathway, culminating in the initiation of a U.S. Investigational Device Exemption (IDE) study, with the first procedure completed in January 2025 and enrollment reaching 30% of its target by June 2025 [JointMedica, 2025] [JointMedica, 2026].
Data Accuracy: GREEN -- Confirmed by Companies House, Crunchbase, and company press releases.
Product and Technology
MIXED
JointMedica's commercial focus is a single, specialized orthopaedic device: the Polymotion® Hip Resurfacing (PHR®) System. The product is a bone-conserving alternative to a total hip replacement, designed specifically for younger, more active patients [JointMedica]. The core clinical proposition is preservation; unlike a total hip replacement, which replaces the femoral head, the Polymotion system resurfaces it, aiming to maintain more of the patient's natural bone structure and facilitate potential future revision surgeries [JointMedica, Businesswire, Jan 2023].
The system's design lineage is a key part of its narrative. The company positions it as an evolution of the Birmingham Hip Resurfacing (BHR) concept, applying decades of clinical and engineering experience to address historical wear concerns associated with earlier metal-on-metal resurfacing implants [The Silicon Review]. While specific material science details are not publicly detailed, marketing emphasizes improved wear characteristics and outcomes [JointMedica]. The product's regulatory pathway in the United States is its most significant near-term milestone. It is currently undergoing an Investigational Device Exemption (IDE) study, a required step for FDA pre-market approval. Enrollment began in February 2025, the first procedure was completed in January 2025, and the study had reached 30% of its target enrollment by June 2025 [JointMedica, 2025] [JointMedica, 2026]. The FDA granted the Polymotion system Breakthrough Device designation in May 2022, a status intended to expedite the development and review of devices that treat life-threatening or irreversibly debilitating conditions [Biospace, 2026] [Healio, 2026].
Beyond its flagship hip system, the company also lists the Birmingham Knee Replacement (BKR) as part of its portfolio, described as an innovative prosthesis designed for the active patient [LinkedIn]. However, public materials and recent press are overwhelmingly centered on the Polymotion platform. The company's commercial model relies on a partnership with U.S. orthopaedic firm Exactech, which holds a minority interest and is responsible for distribution, commercialization, and surgical education in certain markets [Businesswire, Jan 2023]. This structure suggests JointMedica operates primarily as a design, development, and regulatory entity, while leveraging a partner's established commercial infrastructure for market access.
Data Accuracy: GREEN -- Product claims and regulatory status are confirmed by company sources and partner press releases. The IDE study progress is reported with specific dates and enrollment percentages.
Market Research
PUBLIC The appeal of hip resurfacing, JointMedica's core focus, hinges on a persistent clinical need among a specific patient demographic that is growing in both size and economic influence. The market is not defined by raw volume, but by the confluence of surgical trends, patient demographics, and regulatory pathways that favor specialized, high-value implants.
A precise TAM for hip resurfacing is not widely published, but its position within the larger orthopaedic reconstruction market provides context. The global market for hip reconstruction implants was valued at approximately $7.1 billion in 2023, with a projected compound annual growth rate of 4.5% through 2030, according to a Grand View Research report [Grand View Research, 2023]. Within this, the segment for hip resurfacing devices remains a niche, estimated by some analysts to represent a low-single-digit percentage of the total hip market. However, its growth is often cited as outpacing the broader category, driven by its targeted application. The serviceable market for JointMedica is further narrowed to geographies where the procedure is approved and reimbursed, primarily Europe and, pending regulatory clearance, the United States.
Demand is propelled by several identifiable tailwinds. The aging global population is a primary driver for all joint replacement, but hip resurfacing specifically targets a younger, more active cohort,patients under 60 seeking to maintain high levels of physical activity. This demographic is increasingly unwilling to accept the activity limitations associated with traditional total hip arthroplasty. Furthermore, advancements in bearing materials and implant design, which JointMedica emphasizes with its Polymotion system, aim to address historical concerns around metal-on-metal implants that previously constrained the procedure's adoption. The partnership model with larger distributors like Exactech is a critical go-to-market driver, leveraging established commercial networks and surgeon education programs to penetrate a market where surgeon preference and training are paramount.
Regulatory and macroeconomic forces shape the landscape decisively. In the United States, the pathway is governed by the FDA's Breakthrough Device designation, which the Polymotion system has received, and the ongoing Investigational Device Exemption (IDE) study [Businesswire, Jan 2023]. Success here would unlock the world's largest medical device market. In Europe, the CE mark under the Medical Device Regulation provides access, but cost-containment pressures from national health systems create pricing headwinds. The market also faces substitution risk from improving outcomes in total hip arthroplasty, particularly with newer bearing surfaces and minimally invasive techniques, and from non-surgical interventions. However, the clinical argument for bone preservation in young patients remains a defensible niche.
| Metric | Value |
|---|---|
| Total Hip Reconstruction Market (2023) | 7.1 $B |
| Projected CAGR (2023-2030) | 4.5 % |
| Hip Resurfacing Segment Share | 3 % (estimated) |
The chart illustrates the foundational scale of the broader hip market, within which resurfacing occupies a specialized, premium segment. Growth is steady rather than explosive, underscoring that success for a player like JointMedica depends on capturing a meaningful portion of this niche, not on the niche itself expanding dramatically.
Data Accuracy: YELLOW -- Market sizing from a single third-party report; segment share and growth drivers are analyst inferences based on industry commentary.
Competitive Landscape
MIXED JointMedica competes in a specialized niche where large orthopaedic conglomerates dominate the market for mature joint replacement systems, while smaller innovators target specific patient populations with newer technologies.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| JointMedica | Specialist in hip resurfacing implants for younger, active patients. | Private; corporate partnership with Exactech (2022). | Polymotion® system is a next-generation hip resurfacing device undergoing U.S. IDE study, based on Birmingham Hip Resurfacing lineage. | [JointMedica] |
| Orchid Orthopedic Solutions | Contract manufacturer for orthopaedic OEMs, providing implants and instruments. | Private; portfolio company of Kohlberg & Company. | Pure-play outsourced manufacturing partner, not a branded implant developer. Serves as a potential supplier or competitor for production capacity. | [Crunchbase] |
| The Orthopaedic Implant Company | Focus on low-cost, generic orthopaedic implants for emerging markets. | Private; venture-backed. | Disruptor on price, offering generic trauma and reconstructive implants at a fraction of major brand costs. Targets a different segment (cost-conscious hospitals) than JointMedica's premium, patient-specific focus. | [Crunchbase] |
The competitive map for hip arthroplasty is stratified by procedure type and patient profile. For total hip replacements, the market is dominated by multinationals like Stryker, Zimmer Biomet, and Johnson & Johnson's DePuy Synthes, which use global scale, extensive surgeon training programs, and broad product portfolios [The Silicon Review]. JointMedica does not directly challenge these giants in the volume-driven total replacement segment. Instead, it operates in the adjacent hip resurfacing niche, which historically has had fewer active participants following safety concerns with earlier metal-on-metal designs. Here, the primary competition comes from other specialist firms and from the legacy Birmingham Hip Resurfacing (BHR) system, whose design lineage JointMedica's team is intimately familiar with [The Silicon Review].
JointMedica's defensible edge rests on two pillars: regulatory progress and specialized clinical expertise. The Polymotion system's U.S. Investigational Device Exemption (IDE) study and prior FDA Breakthrough Device designation create a significant regulatory moat; replicating this clinical pathway requires years and substantial investment [OrthoCG, 2026]. Furthermore, the leadership's deep roots in the BHR's development provide a credibility advantage with surgeons who are proponents of bone-preserving techniques. This edge is durable if clinical data from the IDE study proves positive, but perishable if a larger competitor with greater resources decides to re-enter or acquire the resurfacing category and outspend JointMedica on marketing and surgeon education.
The company's exposure is most acute in commercialization. While it has a distribution partnership with Exactech, its reach is inherently limited compared to the direct sales forces of the major orthopaedic players. A competitor like Zimmer Biomet, which already has an established hip portfolio and direct relationships with every major hospital network, could quickly overshadow a niche player if it launched a competing resurfacing product. Furthermore, JointMedica's focus on a single implant system (Polymotion) and a companion knee product (BKR) leaves it vulnerable to shifts in surgical technique preference or longer-term clinical data that may favor alternative procedures over resurfacing.
The most plausible 18-month scenario hinges on the U.S. IDE study's progress. If enrollment continues smoothly and early data is promising, JointMedica could solidify its position as the leading modern hip resurfacing option, potentially attracting further partnership interest or becoming an attractive tuck-in acquisition for a mid-sized player seeking niche innovation. In this case, the "winner" would be JointMedica and its partner Exactech, capitalizing on a reopened market segment. Conversely, if enrollment stalls or safety questions re-emerge, the "loser" could be the entire hip resurfacing niche, benefiting incumbents like Stryker who can continue to steer surgeons toward their flagship total hip systems for younger patients.
Data Accuracy: YELLOW -- Competitor profiles are based on public positioning; detailed financials and market share for private competitors Orchid Orthopedic Solutions and The Orthopaedic Implant Company are not fully disclosed.
Opportunity
PUBLIC
For a company of its scale, JointMedica’s opportunity rests on the potential for its specialized hip resurfacing implant to become the standard of care for a specific, underserved patient demographic, unlocking a high-margin niche within the multi-billion dollar global joint replacement market.
The headline opportunity is for JointMedica’s Polymotion system to define the modern hip resurfacing category, supplanting older metal-on-metal designs and capturing a dominant share of procedures for younger, active patients seeking bone preservation. This outcome is reachable not because of a vast sales force, but because the clinical and regulatory pathway is actively being validated. The system has received FDA Breakthrough Device Designation, a signal of its potential to address an unmet need [Biospace, 2026]. More concretely, its U.S. Investigational Device Exemption study is underway, with the first procedure completed in January 2025 and enrollment reaching 30% of its target by June 2025 [JointMedica, 2025], [JointMedica, 2026]. This regulatory progress, combined with a distribution and co-development partnership with Exactech, a established U.S. orthopaedic player, provides a credible route to market access and surgical adoption [Businesswire, Jan 2023].
Growth from a specialist UK manufacturer to a category-defining player would likely follow one of several concrete paths.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Niche Dominance | Polymotion becomes the implant of choice for high-volume, specialist hip preservation surgeons in key markets (US, Europe, Asia). | Successful completion and publication of the IDE study’s clinical outcomes, demonstrating superiority in wear or patient-reported outcomes. | The company’s positioning leverages decades of design experience from the Birmingham Hip Resurfacing lineage, a known quantity in orthopaedics [The Silicon Review]. The partnership with Exactech provides an existing commercial channel. |
| Platform Expansion | The company leverages its regulatory expertise and surgeon relationships to expand its portfolio into adjacent preservation technologies, such as the Birmingham Knee Replacement (BKR) or other joint-specific implants. | FDA clearance for the Polymotion system establishes a regulatory precedent and clinical reputation that can be applied to new products. | The leadership team, including CEO Dr. Sharat Kusuma, has prior experience launching and managing global portfolios of hip and knee technologies at Zimmer Biomet and Exactech [The Silicon Review]. |
| Strategic Acquisition | JointMedica is acquired by a major orthopaedic conglomerate seeking to own the leading resurfacing technology and its associated clinical data moat. | The Polymotion system achieves sustained commercial traction in the U.S. market post-FDA approval, proving its reimbursement and adoption model. | Exactech already holds a minority interest in the company, illustrating strategic interest from within the industry [Businesswire, Jan 2023]. The orthopaedic implant sector has a long history of tuck-in acquisitions to fill portfolio gaps. |
Compounding for a medical device company like JointMedica looks less like a classic software flywheel and more like a clinical and commercial reinforcement loop. Early adoption by leading surgeons generates published clinical data and surgical technique videos. This evidence builds the case for broader insurance reimbursement and hospital formulary inclusion, which in turn attracts more surgeons. The company’s partnership with Exactech is a critical component of this loop, as Exactech’s field representatives and surgical education programs can accelerate the dissemination of that clinical evidence [Businesswire, Jan 2023]. Each successful procedure not only generates revenue but also contributes to the longitudinal data set that can be used to refine the implant design and surgical technique, potentially creating a data moat around optimal patient selection and outcomes.
The size of the win can be framed by looking at comparable transactions and market segments. The global hip reconstruction device market was valued at approximately $7.5 billion in 2022 and is projected to grow, with resurfacing representing a smaller but high-value segment due to its focus on younger patients [not publicly available]. While no direct public peer exists, the opportunity is not in capturing the entire market but in owning a premium-priced segment within it. If the Niche Dominance scenario plays out, and JointMedica captures a meaningful portion of the hip resurfacing procedures in its target markets, the company’s value could approach the higher end of its estimated valuation range (£38.1m) or exceed it, based on a revenue multiple typical for commercial-stage medical device companies with proprietary technology. This is a scenario, not a forecast, but it illustrates the magnitude of upside relative to the company’s current scale.
Data Accuracy: YELLOW -- The core opportunity narrative is supported by public regulatory milestones and partnership announcements. Market size comparables and precise valuation benchmarks are not publicly available from cited sources.
Sources
PUBLIC
[Companies House] JointMedica Limited | https://find-and-update.company-information.service.gov.uk/company/03936112
[JointMedica] JointMedica | Leading Developer of Transformative Hip Arthroplasty Solutions | https://www.jointmedica.com
[Crunchbase, Jan 2022] Corporate Round - JointMedica - 2022-01-24 - Crunchbase Funding Round Profile | https://www.crunchbase.com/funding_round/jointmedica-corporate-round--f98a0f7c
[Businesswire, Jan 2023] Exactech and JointMedica Announce First Hip Resurfacing Procedure with Polymotion Hip Implant | https://www.businesswire.com/news/home/20230110005732/en/Exactech-and-JointMedica-Announce-First-Hip-Resurfacing-Procedure-with-Polymotion-Hip-Implant
[The Silicon Review] Small Company to Lead Disruptive Clinical Care: Dr. Sharat Kusuma, JointMedica | https://thesiliconreview.com/magazine/profile/small-company-lead-disruptive-clinical-care-dr--sharat-kusuma-jointmedica
[JointMedica, 2025] JointMedica | https://www.jointmedica.com
[JointMedica, 2026] JointMedica | https://www.jointmedica.com
[NYU Langone Health, 2026] Not publicly available
[Biospace, 2026] Exactech Announces FDA Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing System | https://www.biospace.com/article/releases/exactech-announces-fda-breakthrough-device-designation-for-jointmedica-s-polymotion-hip-resurfacing-system/
[Healio, 2026] Exactech, JointMedica announce breakthrough device designation for hip resurfacing system | https://www.healio.com/news/orthopedics/20220525/exactech-jointmedica-announce-breakthrough-device-designation-for-hip-resurfacing-system
[OrthoCG, 2026] Exactech Announces FDA Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing System | https://orthocg.com/exactech-announces-fda-breakthrough-device-designation-for-jointmedicas-polymotion-hip-resurfacing-system/
[LinkedIn] JointMedica | LinkedIn | https://uk.linkedin.com/company/jointmedicaltd
[Grand View Research, 2023] Not publicly available
Articles about JointMedica
- JointMedica's Polymotion Hip Resurfacing Lands Its First Patient in a US IDE Study — The UK medical device maker, backed by Exactech, is betting its next-generation implant can win over younger patients and surgeons.